Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Rebekah Gould"'
Autor:
Gloria V. Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B. Redwood, Yan Jiang, Aaron McCoy, Amanda L. Rinkenbaugh, Rosanna Lau, Alexander J. Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E. Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E. Adrada, Deanna L. Lane, Gaiane M. Rauch, Wei T. Yang, Jason B. White, Jeffrey T. Chang, Stacy L. Moulder, W. Fraser Symmans, Susan G. Hilsenbeck, Helen Piwnica-Worms
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patient-derived xenograft (PDX) models of breast cancer are an effective discovery platform and tool for preclinical pharmacologic testing and biomarker identification. We established orthotopic PDX models of triple negative breast cancer (T
Externí odkaz:
https://doaj.org/article/1aeaec90b47b427c8b0d10b0dad9ddf6
Autor:
Sonal Shad, William Fraser Symmans, Debu Tripathy, Lamorna Brown-Swigart, LJ Esserman, Jane Perlmutter, V. Valero, Rebekah Gould, Gregor Krings, Judy C. Boughey, Jodi M. Carter, M. van der Noordaa, Gillian L. Hirst, L.J. van 't Veer, Christina Yau, Douglas Yee, Lajos Pusztai, Tufia C. Haddad, Kathy S. Albain, Molly Klein, Lili Du, MC Liu, Rita Nanda, Claudine Isaacs, Richard Schwab, Amy Jo Chien, Donald A. Berry, Rachel M. Layman, AM DeMichele, Isabelle Bedrosian, Sara J. Venters, Nola M. Hylton
Publikováno v:
Annals of Oncology. 32:642-651
BACKGROUND We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR in
Autor:
Jiaxin Qu, Chunxiao Fu, Rebekah Gould, Todd Pappas, Lili Du, W. Fraser Symmans, Christos Hatzis, Lajos Pusztai, Michal Marczyk, Rosanna Lau, Michael Samuels, Bruno Valentin Sinn, Alexander J. Trevarton
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Our objective was to assess whether modifications to a customized targeted RNA sequencing (RNAseq) assay to include unique molecular identifiers (UMIs) that collapse read counts to their source mRNA counts would improve quantification of t
Autor:
Eveline Chen, Rebekah Gould, Lili Du, Vicente Valero, Rosanna Lau, Rachel M. Layman, Isabelle Bedrosian, Michal Marczyk, Bruno Valentin Sinn, W. Fraser Symmans, Chunxiao Fu
Publikováno v:
Clinical Chemistry. 66:934-945
Background We translated a multigene expression index to predict sensitivity to endocrine therapy for Stage II–III breast cancer (SET2,3) to hybridization-based expression assays of formalin-fixed paraffin-embedded (FFPE) tissue sections. Here we r
Autor:
Lili Du, Christina Yau, Lamorna Brown-Swigart, Rebekah Gould, Gillian L Hirst, I-SPY2 Consortium, Marieke van der Noordaa, Isabelle Bedrosian, Rachel M Layman, Vicente Valero, Laura van't Veer, Laura Esserman, W. Fraser Symmans
Publikováno v:
Cancer Research. 80:P2-11
Background: The SET2,3 index combines an accurate measure of transcription related to both estrogen and progesterone receptors (SETER/PR index) with a baseline prognostic index (BPI) derived from c-T Stage, c-N status and molecular subtype by RNA4 (E
Autor:
Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Sara López-Tarruella, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, Laura J Esserman, W Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita M. Asare, Ron Balassanian, Heather Beckwith, Scott M. Berry, Donald A. Berry, Judy C. Boughey, Meredith B. Buxton, Yunn-Yi Chen, Beiyun Chen, A. Jo Chien, Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace, Shi Wei, Amy Wilson, Douglas Yee, Jay C. Zeck
Publikováno v:
I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b5a03d8d05046179f5dcc364471bd0
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
Autor:
Ya Zhang, Dilip Giri, Esmeralda Celia Marginean, W. Fraser Symmans, Ioanna Laïos, Rashmi Krishna Murthy, Christos Hatzis, Jennifer K. Litton, Ravi Murthy, Alda L. Tam, Agnes Viale, Eleni Andreopoulou, Danielle N. Kwiatkowski, Rebekah Gould, Tsung-Heng Tsai, Tari A. King, Chunxiao Fu, Vicente Valero, Bruno Valentin Sinn, Yun Gong, Daniel J. Booser, Victor P. Andrade, Roberto Salgado, Rosanna Lau, Rachel M. Layman, Christos Sotiriou
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-8 (2019)
NPJ breast cancer, 5 (1
NPJ breast cancer, 5 (1
There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcription
Autor:
Rebekah Gould, Lili Du, Christos Hatzis, Bruno Valentin Sinn, C Fu, Rosanna Lau, Michal Marczyk, William Fraser Symmans, Alexander J. Trevarton
Publikováno v:
Cancer Research. 79:P4-08
Background: The clinical management of patients with metastatic HR-positive breast cancer is often uncertain due to decreased sensitivity to anti-estrogen therapy over time. Recently, we developed a targeted RNAseq based 18-transcript SET ER/PR assay
Autor:
Maria Vittoria Dieci, Stefan Michiels, Eleni Andreopoulou, Sylvia Adams, Timothy M. D'Alfonso, Sandra Demaria, Miluska Castillo, Andrea Vingiani, Giuseppe Curigliano, J. Sanchez, Sherene Loi, Stephen J Luen, Roberto Salgado, William Fraser Symmans, Carlos A. Castaneda, Rebekah Gould, Esther Cheng
Publikováno v:
Annals of Oncology. 30:236-242
For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We eval
Autor:
Lajos Pusztai, Bruno Valentin Sinn, Chunxiao Fu, Christos Hatzis, Rebekah Gould, Lili Du, W. Fraser Symmans, Michal Marczyk, Rosanna Lau, Alexander J. Trevarton
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Background Utilization of RNA sequencing methods to measure gene expression from archival formalin-fixed paraffin-embedded (FFPE) tumor samples in translational research and clinical trials requires reliable interpretation of the impact of pre-analyt